Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993378 | 0.88 | KMT2A (0.47) | KMT2ACYP26A1 | |
| SCHEMBL13742745 | 0.86 | CYP26A1 (0.47) | JAK3BTKCTSKCTSSKMT2A | |
| SCHEMBL22188676 | 0.85 | MEN1 (0.42) | JAK3BTKKMT2AATM | |
| SCHEMBL8171011 | 0.85 | CTSS (0.41) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL4125738 | 0.84 | KMT2A (0.48) | MAPTKMT2ACYP26A1 | |
| SCHEMBL5862217 | 0.83 | CTSK (0.52) | CTSKCTSSMAPTKMT2AATM | |
| SCHEMBL1783805 | 0.83 | CTSK (0.52) | CTSKCTSSMAPTKMT2AATM | |
| SCHEMBL31633773 | 0.83 | CTSK (0.52) | CTSKCTSSMAPTKMT2AATM | |
| SCHEMBL1573513 | 0.83 | CTSK (0.52) | CTSKCTSSMAPTKMT2AATM | |
| SCHEMBL348500 | 0.83 | CTSK (0.54) | CTSKCTSSMAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209578-A1 | CHEMICAL COMPOUNDS | PFIZER INC | 2009-08-20 | — | — | US | disclosed |
| US-20090209578-A1 | CHEMICAL COMPOUNDS | PFIZER INC | 2009-08-20 | — | — | US | disclosed |
| WO-2007066201-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1539695-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1490336-A1 | PIPERIDINE OR 8-AZA-BICYCLO(3.2.1)OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004018425-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1368314-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003080574-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002070479-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | CCR5, CXCR1, CCR7 | JAK3 1981/4885BTK 2883/4885CTSK 3757/4885 |
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | JAK3 2185/4885BTK 1861/4885CTSK 3692/4885 |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | JAK3 2091/4885BTK 1775/4885CTSK 3212/4885 |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | JAK3 2050/4885BTK 2265/4885CTSK 3413/4885 |
| US-20090209578-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CXCR1 | JAK3 1884/4885BTK 1821/4885CTSK 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.